Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | CD3ε |
Clinical data | |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a605011 |
Pregnancy category |
|
Routes of administration |
intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C6460H9946N1720O2043S56 |
Molar mass | 146.091 g/mol |
(what is this?) |
Muromonab-CD3 (trade name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant drug given to reduce acute rejection in patients with organ transplants. It is a monoclonal antibody targeted at the CD3 receptor, a membrane protein on the surface of T cells. It was the first monoclonal antibody to be approved for clinical use in humans.
Muromonab-CD3 (OKT3) was approved by the U.S. Food and Drug Administration (FDA) in 1985, making it the first monoclonal antibody to be approved anywhere as a drug for humans. In the European Communities, it was the first drug to be approved under the directive 87/22/EWG, a precursor of the European Medicines Agency (EMEA) centralised approval system in the European Union. This process included an assessment by the Committee for Proprietary Medicinal Products (CPMP, now CHMP), and a subsequent approval by the national health agencies; in Germany, for example, in 1988 by the Paul Ehrlich Institute in Frankfurt. However, the manufacturer of Muromonab-CD3 has voluntarily withdrawn it from the United States market due to decreased utilization; current OKT3 supplies are expected to be exhausted by mid-2010.
Muromonab-CD3 is approved for the therapy of acute, glucocorticoid-resistant rejection of allogeneic renal, heart and liver transplants. Unlike the monoclonal antibodies basiliximab and daclizumab, it is not approved for prophylaxis of transplant rejection, although a 1996 review has found it to be safe for that purpose.